QuidelOrtho Corporation (QDEL)

NASDAQ • Healthcare

$13.42

+$1 (+8.1%)

Market closed

Last close at October 9, 2026 at 20:00 UTC

Open$12.52

Day Range$12.21 - $13.62

Avg. Volume (3M)1.9M

Market Cap$915.1M

52 Week Range

$9.92$35.58

Next EarningsIn 25 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$630.9M100%

Gross Profitminus cost of goods$272.9M43%

In plain terms: out of every $100 in revenue, QuidelOrtho Corporation currently loses $15.

Fundamentals & Financials

Revenue (TTM)

$2.6B

Net Income (TTM)

-$1B

EPS (TTM)

-$15.44

ROA (TTM)

-18.34%

Current Ratio

1.39

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+7743.1%Q3 2025$0.12

+56.9%Q4 2025$0.8

+7.0%Q1 2026$0.46

-110.8%Q2 2026-$0.04

+366.2%Q3 2026$0.13

Nov 4

in 25 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +366.2%

QuidelOrtho's adjusted EPS of $0.13, up about 8% from $0.12 a year earlier, topped the -$0.05 estimate by about 366% in the fiscal second quarter of 2026, reported August 6 on preliminary results, while revenue rose about 3% to about $630.9 million with gross margin near 43%. Labs remained the largest segment at about $353.1 million, down about 5%, while Point of Care fell 34% to about $112.8 million and Donor Screening dropped 39% to about $7.8 million. Gross profit came in at about $272.9 million, net income improved 64% to negative about $92.9 million from negative $255.4 million a year ago, and operating cash flow was negative $110.6 million.

Next report — what to expect

QuidelOrtho Corporation (QDEL) reports next on November 4, 2026. Wall Street looks for EPS of $0.202 on revenue of $628.1 million. For trailing context, revenue grew +2.8% year over year last quarter. QDEL has beaten EPS in 7 of 8 most recent quarters, keeping attention on margins and demand trends.

View full earnings history

About QuidelOrtho Corporation

QuidelOrtho Corporation is a healthcare diagnostics company listed on NASDAQ as QDEL that makes testing systems and supplies for laboratories, near-patient settings, and molecular analysis. In FY2025 it generated $2.7 billion in revenue. Its business sits in the medical instruments and supplies field and spans a broad range of healthcare testing needs.

Name

QuidelOrtho Corporation

CEO

Brian J. Blaser

Website

www.quidelortho.com

Industry

Healthcare

Year Founded

1979

Employees

6,500

Today's Snapshot

AI-generated

The day ended with QDEL 8.1% higher at 13.42, in line with a firmer sector. Trading was busier than usual, with volume about half as much again as its usual level.

Trading Volume

Above 10d avg 2.3M

3.4M

vs S&P 500 Today

Strong Outperformance

+7.55%

Updated: October 9, 2026 at 20:08 UTC

QDEL Headlines

Healthcare stocks fall after weak US jobs data

March 6, 2026

3 min read

View All News

Technical Indicators

3 Buy2 Neutral3 Sell

QDEL shows a mixed technical profile: the ADX near 29 suggests a borderline strengthening trend while momentum readings are conflicted, with RSI in the low 60s and a very strong CCI reading that signals upside pressure even as stochastic and Williams %R register overbought conditions. Price sits above short- and medium-term moving averages but remains well below the 100– and 200-day averages, creating tension between near-term strength and longer-term resistance. Volatility is elevated by ATR and OBV points to accumulation despite a negative absolute level; the pivot around 12.24 offers nearby support. Technical takeaway: Neutral — short-term strength clashes with longer-term resistance.

All signals